Highest-materiality recent filing
Cencora Q2 revenue $78.4B (+3.8%); adj. EPS $4.75 (+7.5%); FY2026 guidance raised
GAAP diluted EPS $8.40 vs $3.68; adjusted diluted EPS $4.75 vs $4.42 (+7.5%).
Cencora to buy EyeSouth retina business for $1.1B; expects slight EPS accretion
Acquires EyeSouth Partners' retina business for $1.1B; physicians to join Retina Consultants of America.
Cencora CFO James F. Cleary to retire June 30, 2026; FY2026 guidance reaffirmed
James F. Cleary, EVP and CFO, will retire effective June 30, 2026; advisory role through end of 2026.
MWI valued at $3.5B enterprise value; Cencora gets $1.25B cash, $800M preferred units, $1.45B common units.
Cencora closes $3.0B senior notes offering, proceeds to repay OneOncology acquisition debt
$500M each of 3.950% notes due 2029, 4.250% notes due 2030, 4.600% notes due 2033, 5.650% notes due 2056; $1.0B of 4.900% notes due 2036.
$3.0B aggregate of senior notes in five tranches: 2029 (3.950%), 2030 (4.250%), 2033 (4.600%), 2036 (4.900%), 2056 (5.650%).
New segments: U.S. Healthcare Solutions, International Healthcare Solutions, and Other.
Cencora Q1 EPS $2.87 GAAP, $4.08 adjusted; acquires OneOncology for $4.6B
Revenue $85.9B, +5.5% YoY; GAAP diluted EPS $2.87 vs $2.50 prior year; adjusted diluted EPS $4.08 vs $3.73, +9.4%.
Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced
Revolving credit facility increased by $1.0B to $5.5B via amendment on Jan 12, 2026.
Cencora acquires OneOncology majority stake for $3.6B, retires $1.3B debt; total cash ~$5.0B
Enterprise value $7.4B; Cencora paying $3.6B for majority equity and retiring $1.3B OneOncology debt.
Cencora Q4 adj EPS $3.84 (+15%); revenue $83.7B; raises dividend 9%; new segment structure
Q4 GAAP diluted EPS $(1.75) (prior yr $0.02); adjusted EPS $3.84 (+15% YoY); revenue $83.7B (+5.9%).
Cencora reaches $111.3M settlement of derivative suit over opioid oversight
Insurance carriers to pay Cencora $111.3M (less attorney fees) to settle derivative claims over controlled substance diversion controls.
Cencora Q3 FY2025 revenue $80.7B (+8.7% YoY); adj. EPS $4.00, guidance raised to $15.85-$16.00
Revenue $80.7B (+8.7% YoY); GAAP diluted EPS $3.52 vs $2.42; adj. EPS $4.00, up 19.8%.
Cencora upsizes revolver to $4.5B, extends maturity to 2030; terminates $1.0B 364-day facility
Amended revolving credit facility increased to $4.5 billion aggregate commitments; maturity extended to June 4, 2030.
Cencora issues €1B in senior notes across 2028 and 2032 maturities
Issued €500M of 2.875% Senior Notes due May 22, 2028.
the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Lori J. Ryerkerk to serve on the Board (the “Appointment”), with such Appointment to be effective as of June 1, 2025
Ornella Barra informed the Company of her intent to resign from the Board effective immediately
Max materiality 0.90 · Median 0.60 · Most common event debt